MultiOmic Health and Alloy Therapeutics Join Forces to Develop Precision Kidney Therapies
MultiOmic Health Limited (MOH), an artificial intelligence-based precision medicine discovery company, has entered into a strategic partnership with Alloy Therapeutics, a biotechnology platform company that aims to democratize access to drug discovery capabilities.
The collaboration seeks to create a novel class of renal-targeted therapeutics for chronic kidney diseases, which would cover unmet medical needs in particular patient subpopulations.
Progressing Precision Medicine for Chronic Kidney Disease
The partnership will target the detection and treatment of subpopulations of patients that are rapid progressors and non-responders to current drugs. MOH has developed AI-powered patient stratification models and uncovered novel drug targets to improve therapeutic precision and efficacy.
Alloy Therapeutics will apply its bispecific antibody and genetic medicine platforms to design therapies that precisely modulate MOH’s identified targets in kidney-specific cells. MOH will contribute its expertise in renal biology and pharmacology to help select the most promising drug candidates for preclinical development.
Industry Leaders Endorse Collaboration
Mike Schmidt, Alloy Therapeutics’ Chief Scientific Office, said, “We were impressed by MOH’s patient stratification and target discovery platform while reviewing the drug targets they proposed.”
He added, “Their deep expertise in disease biology, pharmacology and exploratory drug development is rooted in several individuals with track records of taking assets to clinical stage and approval, complementing our own capabilities very well.”
Also read: China’s CIBR and NeuCyber Speed Up Brain-Computer Interface Trials After Initial Success
Formation of New Venture: RenalDevCo
To accelerate the development of these therapies, Alloy’s venture studio, 82VS, will launch a new company, tentatively named RenalDevCo. This asset-centric entity will license intellectual property from both MOH and Alloy.
In return, both companies will receive significant equity stakes, development milestone payments, and single-digit royalties. MOH will also be compensated for providing research and development support through the IND-enabling and clinical trial phases.
